Anadys Pharmaceuticals, Inc (ANDS) - Financial and Strategic Analysis
Review
Reference Code: GDPH66491FSA Publication Date: SEP 2010
5871 Oberlin Drive, Suite Phone Revenue
+1 858 5303600 0.0 (million USD)
200
San Diego, CA Fax +1 858 5271540 Net Profit -27.28 (million USD)
92121 Website www.anadyspharma.com Employees 30
United States Exchange ANDS [NASDAQ] Industry Pharmaceuticals & Healthcare
Company Overview
Anadys Pharmaceuticals, Inc. (Anadys) is a biopharmaceutical company that develops novel therapeutics for the treatment of
chronic hepatitis C viral infections and cancer. The company is in development stage without any commercialized products. It
generates revenue from collaboration agreements of product development and commercialization with many pharmaceutical
companies. It focuses on research and development of three products with two products for the diagnosis of hepatitis C and one
product for cancer. The company is headquartered in San Diego in California, the US.
Key Executives SWOT Analysis
Name Title Anadys Pharmaceuticals, Inc, SWOT Analysis
Steve Worland, Ph.D. Chief Executive Officer Strengths Weaknesses
Steven H. Holtzman Chairman
Broad Patent Portfolio Negative Margins
Mark G. Foletta Director
Marios Fotiadis Director Sturdy R&D Activities Limited Liquidity Position
Stelios Papadopoulos, Ph.D. Director
Source: Annual Report, Company Website, Primary and Secondary Research
GlobalData
Opportunities Threats
Share Data
HCV-Market Potential Intense Competition
Anadys Pharmaceuticals, Inc
Share Price (USD) as on 08-Sep-2010 1.80 Rising Healthcare Expenditure Tightening of FDA’s
-0.81 in the US Regulatory Oversight
EPS (USD)
Market Cap (million USD) 76
Enterprise Value (million USD) 67
Source: Annual Report, Company Website, Primary and Secondary Research
Shares Outstanding (million) 43 GlobalData
Source: Annual Report, Company Website, Primary and Secondary Research
GlobalData
Financial Performance Recent Developments